Evert Schimmelpennink

Evert Schimmelpennink has served as a member of the board of directors since January 2022. Mr. Schimmelpennink is currently the President and Chief Executive Officer of LENZ Therapeutics, a private biotechnology company. From August 2017 to October 2020 he was the Chief Executive Officer of Pfenex Inc. (NYSE: PFNX), which he led through a turnaround and its first FDA approval resulting in an acquisition by Ligand Pharmaceuticals Inc. in late 2020. From October 2015 to July 2017, Mr. Schimmelpennink was Chief Executive Officer of Alvotech, a private specialty biopharmaceutical company, where he led the company through a critical growth phase, and aligned R&D, manufacturing and commercial capabilities across a portfolio of monoclonal antibodies. Prior to that, he held senior positions at Pfizer Inc. and Hospira, Inc. within their global specialty injectables businesses, as well as Synthon BV. Mr. Schimmelpennik also serves on the board of directors of IBio, Inc. (NYSE:iBIO).

Mr. Schimmelpennink earned an M.Sc. in bioprocess engineering from the University of Wageningen in the Netherlands and a Business Degree from the Arnhem Business School.